Journal ArticleDOI
Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study
Marc Decramer,Kenneth R. Chapman,Ronald Dahl,Peter Frith,Gilles Devouassoux,Carlos Cezar Fritscher,Ray Cameron,Muhammad Shoaib,David Lawrence,David Young,Danny McBryan +10 more
Reads0
Chats0
TLDR
Indacaterol and tiotropium provided clinically relevant improvements in lung function with comparable safety profiles and the present data offer evidence consistent with current guidelines.About:
This article is published in The Lancet Respiratory Medicine.The article was published on 2013-09-01. It has received 230 citations till now. The article focuses on the topics: Tiotropium bromide & Indacaterol.read more
Citations
More filters
Journal ArticleDOI
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary.
Jørgen Vestbo,Suzanne S. Hurd,Alvar Agusti,Paul W. Jones,Claus Vogelmeier,Antonio Anzueto,Peter J. Barnes,Leonardo M. Fabbri,Fernando J. Martinez,Masaharu Nishimura,Robert A. Stockley,Don D. Sin,Roberto Rodriguez-Roisin +12 more
TL;DR: It is recommended that spirometry is required for the clinical diagnosis of COPD to avoid misdiagnosis and to ensure proper evaluation of severity of airflow limitation.
Journal ArticleDOI
Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary
Claus Vogelmeier,Gerard J. Criner,Fernando J. Martinez,Antonio Anzueto,Peter J. Barnes,Jean Bourbeau,Bartolome R. Celli,Rongchang Chen,Marc Decramer,Leonardo M. Fabbri,Peter Frith,David M.G. Halpin,M. Victorina López Varela,Masaharu Nishimura,Nicolas Roche,Roberto Rodriguez-Roisin,Don D. Sin,Dave Singh,Robert Stockley,Jørgen Vestbo,Jadwiga A. Wedzicha,Alvar Agusti +21 more
TL;DR: The assessment of chronic obstructive pulmonary disease has been refined to separate the spirometric assessment from symptom evaluation, and the concept of deescalation of therapy is introduced in the treatment assessment scheme.
Journal ArticleDOI
Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary
Claus Vogelmeier,Gerard J. Criner,Fernando J. Martinez,Antonio Anzueto,Peter J. Barnes,Jean Bourbeau,Bartolome R. Celli,Rongchang Chen,Marc Decramer,Leonardo M. Fabbri,Peter Frith,David M.G. Halpin,M. Victorina López Varela,Masaharu Nishimura,Nicolas Roche,Roberto Rodriguez-Roisin,Don D. Sin,Dave Singh,Robert Stockley,Jørgen Vestbo,Jadwiga A. Wedzicha,Alvar Agusti +21 more
TL;DR: The assessment of COPD has been refined to separate the spirometric assessment from symptom evaluation, and the concept of de-escalation of therapy is introduced in the treatment assessment scheme.
Journal ArticleDOI
Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary
Claus Vogelmeier,Gerard J. Criner,Fernando J. Martinez,Antonio Anzueto,Peter J. Barnes,Jean Bourbeau,Bartolome R. Celli,Rongchang Chen,Marc Decramer,Leonardo M. Fabbri,Peter Frith,David M.G. Halpin,M. Victorina López Varela,Masaharu Nishimura,Nicolas Roche,Roberto Rodriguez-Roisin,Don D. Sin,Dave Singh,Robert Stockley,Jørgen Vestbo,Jadwiga A. Wedzicha,Alvar Agusti +21 more
TL;DR: The assessment of chronic obstructive pulmonary disease has been refined to separate the spirometric assessment from symptom evaluation, and the concept of de‐escalation of therapy is introduced in the treatment assessment scheme.
Journal ArticleDOI
Chronic obstructive pulmonary disease
Klaus F Rabe,Henrik Watz +1 more
TL;DR: Without a global political and economic effort to reduce tobacco use, to regulate environmental exposure, and to find alternatives to the massive use of biomass fuel, COPD will remain a major health-care problem for decades to come.
References
More filters
Journal ArticleDOI
Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study
Jadwiga A. Wedzicha,Marc Decramer,Joachim H. Ficker,Dennis E. Niewoehner,Thomas Sandström,Angel Fowler Taylor,Peter D'Andrea,Christie Arrasate,Hungta Chen,Donald Banerji +9 more
TL;DR: The dual bronchodilator QVA149 was superior in preventing moderate to severe COPD exacerbations compared with the single longacting antimuscarinic bronchidilator glycopyrronium, with concomitant improvements in lung function and health status.
Journal ArticleDOI
Impact of preventing exacerbations on deterioration of health status in COPD.
TL;DR: In this paper, the effect of fluticasone propionate (FP) on exacerbations of chronic obstuctive pulmonary disease (COPD) is associated with worse health status.
Journal ArticleDOI
Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: GOLD Executive Summary updated 2003.
TL;DR: The definition and classification of Severity and its applications are explained in detail in Table 1.1.
Journal ArticleDOI
Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium.
James F. Donohue,Charles Fogarty,Jan Lötvall,Donald A. Mahler,Heinrich Worth,Arzu Yorgancioglu,Amir Iqbal,James Swales,Roger Owen,Mark Higgins,Benjamin Kramer +10 more
TL;DR: Indacaterol was an effective once-daily bronchodilator and was at least as effective as tiotropium in improving clinical outcomes for patients with COPD.